Garabit Viaduct: Transforming Breakthrough Ideas into Standardized Reality.

When Gustave Eiffel engineered the Garabit Viaduct—then the world's highest arch bridge—it served as a proving ground where pioneering innovation met standardized precision, laying the blueprint for the iconic Eiffel Tower. Bringing an innovative molecule to light requires the exact same approach.

At Bridge to Trial, we translate breakthrough science into a structured, rigorous, and fully compliant preclinical package. By combining strategic foresight with meticulous IND-enabling studies, we turn complex data into a compliant bridge that reliably supports your transition into human trials.

Preclinical Package & Asset Derisking Services

Bridging the gap between early discovery and first-in-human (FIH) clinical trials requires a robust, cohesive strategy that aligns non-clinical safety, Chemistry, Manufacturing, and Controls (CMC), and regulatory planning. Our Preclinical Package services are designed to evaluate, optimize, and execute your asset’s non-clinical roadmap, ensuring a seamless, de-risked transition into clinical development.

1. Preclinical Package Review & CDP/TPP Alignment

  • Comprehensive Package Auditing: In-depth review of existing non-clinical data to evaluate readiness for regulatory interactions and clinical entry.
  • Strategic Roadmap Integration: Initiating and driving strategic discussions regarding your Target Product Profile (TPP) and Clinical Development Plan (CDP) to ensure your non-clinical strategy serves your ultimate commercial and clinical goals.
  • Gap Analysis: Identifying critical package gaps to bring your candidate to the clinic in compliance with your TPP, CDP and regulatory requirements.
Strategic Foundation

2. Non-Clinical CRO Selection, Contracting & Vendor Management

  • Expert Partner Matching: Identifying and vetting suitable non-clinical Contract Research Organization (CRO) vendors and toxicology specialists tailored to your asset.
  • Contract Support: Supporting or overseeing the negotiation of Statements of Work (SOWs), Master Services Agreements (MSAs), and Quality Agreements with external partners.
  • Seamless Vendor Oversight: Managing day-to-day interactions, new studies coordination, and emerging data oversight.
Vendor Governance

3. Financial Modeling & Budget Management

  • Cost Modeling & Forecasting: Building detailed financial models and scenario-based cost forecasts for non-clinical and manufacturing campaigns.
  • Budget Tracking: Monitoring ongoing vendor expenditures against contract scopes to prevent budget overruns and optimize cash flow management.
  • Integrated Timelines Development: Building master timelines to synchronize tox studies and IP supply.
Financial Oversight

4. CMC & Investigational Product (IP) Supply Strategy

  • Supply Chain & Needs Assessment: Evaluating requirements for preclinical and safety study drug supplies.
  • Route Scouting & Evaluation: Reviewing synthetic routes for scalability and proposing alternatives if needed.
  • CDMO Identification & Management: Selecting, and managing suitable Contract Development and Manufacturing Organizations (CDMOs) for drug substance preparation and formulation.
CMC & Manufacturing

5. Quality Assurance & Regulatory Readiness

  • GLP/GMP Alignment: Ensuring vendor studies meet Good Laboratory and Manufacturing Practice standards.
  • Regulatory Agency Interactions: Planning Pre-IND / Scientific Advice meetings with the FDA or EMA.
  • Regulatory Dossier Coordination: Driving the preparation of the Investigator’s Brochure (IB), IMPD, and Phase 1 protocol synopsis.
  • Phase 1 Readiness: Assessing baseline requirements for Phase 1 execution and leading the coordination and authoring of the protocol synopsis and study design.
Regulatory and QA

How We Deliver Value

By combining deep scientific rigor - rooted in advanced organic chemistry and translational research - with seasoned project management, financial oversight, and vendor governance, we eliminate silos between non-clinical safety, manufacturing, and clinical operations. Let us help you de-risk your asset, and accelerate your path to the clinic.